American Association for Cancer Research
Browse
00085472can170164-sup-177665_2_supp_4161582_5t3kt7.png (2.03 MB)

Figure S4 from Androgen Receptor Variants Mediate DNA Repair after Prostate Cancer Irradiation

Download (2.03 MB)
figure
posted on 2023-03-31, 00:42 authored by Yi Yin, Rui Li, Kangling Xu, Sentai Ding, Jeffrey Li, GuemHee Baek, Susmita G. Ramanand, Sam Ding, Zhao Liu, Yunpeng Gao, Mohammed S. Kanchwala, Xiangyi Li, Ryan Hutchinson, Xihui Liu, Solomon L. Woldu, Chao Xing, Neil B. Desai, Felix Y. Feng, Sandeep Burma, Johann S. de Bono, Scott M. Dehm, Ram S. Mani, Benjamin P.C. Chen, Ganesh V. Raj

ARVs are recruited to DNA damage sites.

Funding

Department of Defense

NIH

National Aeronautics and Space Administration

Mimi and John Cole Prostate Cancer Fund

History

ARTICLE ABSTRACT

In prostate cancer, androgen deprivation therapy (ADT) enhances the cytotoxic effects of radiotherapy. This effect is associated with weakening of the DNA damage response (DDR) normally supported by the androgen receptor. As a significant number of patients will fail combined ADT and radiotherapy, we hypothesized that DDR may be driven by androgen receptor splice variants (ARV) induced by ADT. Investigating this hypothesis, we found that ARVs increase the clonogenic survival of prostate cancer cells after irradiation in an ADT-independent manner. Notably, prostate cancer cell irradiation triggers binding of ARV to the catalytic subunit of the critical DNA repair kinase DNA-PK. Pharmacologic inhibition of DNA-PKc blocked this interaction, increased DNA damage, and elevated prostate cancer cell death after irradiation. Our findings provide a mechanistic rationale for therapeutic targeting of DNA-PK in the context of combined ADT and radiotherapy as a strategy to radiosensitize clinically localized prostate cancer. Cancer Res; 77(18); 4745–54. ©2017 AACR.